JNNP: Clinical efficacy of different doses of the athroposis interval drug treatment in patients with multiple sclerosis in Italy.

NTZ;Tysabri is a human-origin anti-alpha4 monoclonal antibody that blocks the adhesion of lymphocytes to endodermal cells, preventing their migration to the central nervous system (CNS) and reducing inflammation.
NTZ's safety and effective studies in the Relapse-Remission Multiple Sclerosis Study showed that NTZ was able to reduce annualized recurrence rate (ARR) by 68 percent, the cumulative accumulation of new or expanded high-intensity lesions by 83 percent, 42 percent progression in 12 weeks of persistent disability, and 54 percent progression in 24 weeks of continuous disability compared to placebo.
NTZ is one of the most effective treatments for multiple sclerosis (MS).
study aims to compare with the standard four-week dosing strategy.
to assess the effectiveness, materials and methods of NTZ in people with multiple sclerosis in Italy: This retrospective multi-center study included patients with relapsed relapsed remission-relieved multiple sclerosis (RR-MS) treated with NTZ between June 1, 2012 and May 15, 2018, followed by an "Italian MS registration."
all MS patients were divided into two groups according to the NTZ dosing schedule: standard interval dosing (SID) patients (average 28-32 days) and extended interval dosing (EID), including 33-49 days (median 43).
clinical data at baseline screening (before starting NTZ), 12 months of treatment (T1) and 24 months (T2).
results: Of the 5,231 RR-MS patients, 2,092 (average age 43.2±12.0, 60.6% female) received NTZ treatment.
A total of 1,254 people (59.9%) received NTZ treatment, according to SID, and 838 people (40.1%) received NTZ treatment.
at 12 and 24 months, there was no difference in annual recurrence rates and disability between the two groups.
two groups of progress indices were similar to the confirmed deterioration of disability.
doctors who treat people with multiple sclerosis have been trying to balance the risks and benefits of this highly effective drug.
number of EID patients has reflected a tendency between Italian clinicians to deviate from monthly SID and delay NTZ delivery depending on the patient's condition.
NTZ with extended intervals shows a similar effect compared to SID.
clinical efficacy of the EID program may cause problems that may have advantages in terms of tolerance and safety.
MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that state "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here.